Controversy Rages Over Diabetes Drug's Heart Risks

Related Newser Stories

• Diabetes Drug Given Strictest Warning Label

  Nov 14, 07 3:20 PM CST
  The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA officials say the agency remains split on the wisdom of pulling the drug immediately. More »

• New Blood Thinner Tops Plavix in Trials

  Nov 5, 07 9:00 AM CST
  An experimental new blood-thinner looks like real competition for top-selling anti-clotting drug Plavix, after proving more effective at preventing heart attacks, strokes, and heart-related death in a recent trial, the AP reports. But “there is a price to pay” for increased effectiveness, wrote one doctor—the new drug caused an extra bleeding death for each heart-related one it prevented. More »

• FDA Panel Votes to Keep Avandia on Shelves

  Jul 30, 07 5:38 PM CDT
  An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

• Glaxo Stems Stock Slide Over Avandia

  May 31, 07 6:44 AM CDT
  Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small. More »

• FDA Warned of Avandia Risks Years Ago

  May 24, 07 1:56 PM CDT
  A diabetes doctor warned the FDA of heart risks posed by the diabetes drug Avandia seven years ago, the New York Times reports. The same concerns raised by Dr. John Buse in a 2000 letter were reiterated in a study published by cardiologist Steven Nissen this week. More »